MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1α and Enhances β-Catenin Signaling
Pingyu Zhang(Shenzhen University), Dina Lev(Assuta Medical Center), Dolores López Terrada(The University of Texas MD Anderson Cancer Center), Elizabeth G. Demicco(Harvard University), Chad J. Creighton(Baylor College of Medicine), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Matthew L. Anderson(Institute for Molecular Medicine), Raphael E. Pollock(The University of Texas MD Anderson Cancer Center), Katelynn Bill(The University of Texas MD Anderson Cancer Center), Eric D. Young(The University of Texas MD Anderson Cancer Center), Juehui Liu(The University of Texas MD Anderson Cancer Center), Svetlana Bolshakov(The University of Texas MD Anderson Cancer Center), Yechun Song(Zunyi Medical University), Aviad Hoffman(The University of Texas MD Anderson Cancer Center), George G. Calin(The University of Texas MD Anderson Cancer Center), Tingsheng Peng(Sun Yat-sen University)
Cited by 111
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k